The Geneva Antibody Facility (GAF) was created in 2004 by researchers at the University of Geneva, in an effort to provide the research community with easy, affordable access to well-characterized rAbs.

The growth on the number of fellow researchers asking for recombinant antibodies (either developed by the GAF, or available at the ABCD database) led to the establishment of ABCD Antibodies in 2022, to operate the commercial facet, not possible inside the university sphere.